Novartis completes acquisition of Avidity Biosciences

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
The new BMW Group Plant Munich: More efficient, more flexible and more...
Double victory: BMW iX3 named "World Car of the Year" and ...
BROKIS at EDC Releases Factory Tour Film of 200-Year-Old Czech...
Unlocking economic potential for high country...
Keeping children in classrooms and supporting schools through fuel...
Foreign Minister appoints Simpson as Deputy Chair of Antarctica New...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

Novartis completes acquisition of Avidity Biosciences

Swiss pharmaceutical company Novartis AG (SIX: NOVN, NYSE: NVS) said on Friday that it has completed its acquisition of Avidity Biosciences, first announced on 26 October 2025.
Avidity Biosciences has now become an indirect wholly owned subsidiary of the company, adding Avidity's...

If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search